Price T Rowe Associates Inc. MD Has $358.32 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Price T Rowe Associates Inc. MD lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 8.4% in the first quarter, Holdings Channel reports. The firm owned 1,322,454 shares of the medical research company’s stock after selling 120,721 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Charles River Laboratories International were worth $358,320,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of CRL. Blue Trust Inc. increased its stake in Charles River Laboratories International by 21.9% in the fourth quarter. Blue Trust Inc. now owns 985 shares of the medical research company’s stock valued at $233,000 after acquiring an additional 177 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Charles River Laboratories International by 5.7% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company’s stock worth $266,000 after buying an additional 61 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Charles River Laboratories International by 5.1% during the 4th quarter. Fifth Third Bancorp now owns 12,062 shares of the medical research company’s stock worth $2,851,000 after buying an additional 580 shares during the last quarter. Norris Perne & French LLP MI boosted its stake in Charles River Laboratories International by 27.1% in the fourth quarter. Norris Perne & French LLP MI now owns 131,993 shares of the medical research company’s stock valued at $31,203,000 after buying an additional 28,103 shares in the last quarter. Finally, DAVENPORT & Co LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at about $1,904,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Up 5.3 %

CRL traded up $11.66 during midday trading on Friday, hitting $233.47. The company had a trading volume of 646,236 shares, compared to its average volume of 451,382. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. The stock’s 50 day moving average price is $212.96 and its 200 day moving average price is $230.20. The company has a market capitalization of $12.03 billion, a price-to-earnings ratio of 27.47, a PEG ratio of 2.23 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $997.24 million. On average, research analysts anticipate that Charles River Laboratories International, Inc. will post 10.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating for the company in a report on Wednesday, July 10th. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. TD Cowen decreased their price target on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research report on Monday, May 13th. Finally, Mizuho began coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They set a “neutral” rating and a $235.00 price target on the stock. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $252.29.

Insider Activity

In related news, EVP Joseph W. Laplume sold 1,304 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).